Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 19 November 2019. Benjamin Bertrand.

Executive Summary

Cardiawave's non-invasive ultrasound therapy is feasible and safe in patients with severe symptomatic aortic stenosis, according to early trial results presented at the annual American Heart Association meeting. See what Cardiawave's CEO, Benjamin Bertrand, said about it here.

“We’re working early on to make sure clinical trial, endpoints, sample size and follow-up data requirements [are discussed with the reimbursement bodies] to help with reimbursement. As you know, reimbursement in each EU country is different, so we’re having those conversations with the relevant organizations early." – Benjamin Bertrand, CEO, Cardiawave

Find out more: AHA 2019: Cardiawave Sees Positive Early Results For Non-Invasive 'Alternative' To TAVR

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

MT125913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel